<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lipid Modification for CVD Prevention | Quick Reference</title>
    <script src="https://kit.fontawesome.com/6c2d277567.js" crossorigin="anonymous"></script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Lato:wght@400;700;900&display=swap" rel="stylesheet">
    <style>
        :root {
            --primary-color: #005A9C;
            --secondary-color: #00A9E0;
            --accent-color-primary: #00B578;
            --accent-color-secondary: #FF8A00;
            --bg-color: #f8f9fa;
            --card-bg: #ffffff;
            --text-color: #343a40;
            --light-text-color: #6c757d;
            --border-color: #dee2e6;
            --shadow: 0 4px 12px rgba(0, 0, 0, 0.08);
            --border-radius: 12px;
        }

        body {
            font-family: 'Lato', sans-serif;
            background-color: var(--bg-color);
            color: var(--text-color);
            line-height: 1.6;
            margin: 0;
            padding: 20px;
        }

        .container {
            max-width: 1400px;
            margin: auto;
            padding: 20px;
        }

        header {
            text-align: center;
            margin-bottom: 40px;
        }

        header h1 {
            color: var(--primary-color);
            font-size: 2.8rem;
            font-weight: 900;
            margin-bottom: 5px;
        }

        header p {
            color: var(--light-text-color);
            font-size: 1.1rem;
            max-width: 800px;
            margin: 0 auto;
        }

        .pathways-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 30px;
            margin-bottom: 40px;
        }

        .pathway-card {
            background: var(--card-bg);
            border-radius: var(--border-radius);
            padding: 30px;
            box-shadow: var(--shadow);
            border-top: 5px solid;
            transition: transform 0.3s ease, box-shadow 0.3s ease;
        }
        
        .pathway-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 8px 20px rgba(0,0,0,0.1);
        }

        .primary-path {
            border-color: var(--secondary-color);
        }

        .secondary-path {
            border-color: var(--primary-color);
        }

        .pathway-card h2 {
            font-size: 2rem;
            font-weight: 700;
            margin-top: 0;
            margin-bottom: 25px;
            display: flex;
            align-items: center;
        }
        
        .primary-path h2 { color: var(--secondary-color); }
        .secondary-path h2 { color: var(--primary-color); }

        .pathway-card h2 i {
            margin-right: 15px;
            font-size: 1.8rem;
        }

        .pathway-card h3 {
            font-size: 1.25rem;
            color: var(--primary-color);
            border-bottom: 2px solid var(--border-color);
            padding-bottom: 8px;
            margin-top: 30px;
            margin-bottom: 15px;
        }

        .pathway-card ul, .pathway-card ol {
            padding-left: 20px;
        }

        .pathway-card li {
            margin-bottom: 10px;
        }
        
        .pathway-card li::marker {
            font-weight: bold;
        }

        .target-box {
            background-color: #e8f7f4;
            border-left: 5px solid var(--accent-color-primary);
            padding: 15px 20px;
            margin: 20px 0;
            border-radius: 8px;
        }
        
        .secondary-path .target-box {
            background-color: #fff4e6;
            border-left-color: var(--accent-color-secondary);
        }

        .target-box p {
            margin: 0;
            font-weight: 700;
            font-size: 1.1rem;
            display: flex;
            align-items: center;
        }
        
        .primary-path .target-box p { color: #006D44; }
        .secondary-path .target-box p { color: #b36200; }

        .target-box i {
            margin-right: 12px;
            font-size: 1.4rem;
        }
        
        .info-box {
            background-color: #f0f4f8;
            border-left: 5px solid var(--light-text-color);
            padding: 15px 20px;
            margin: 20px 0;
            border-radius: 8px;
        }
        
        .info-box h4 {
            margin: 0 0 10px 0;
            font-weight: 700;
            display: flex;
            align-items: center;
        }
        
        .info-box i {
            margin-right: 10px;
        }

        .safety-section {
            background: var(--card-bg);
            border-radius: var(--border-radius);
            padding: 30px;
            box-shadow: var(--shadow);
            margin-top: 20px;
        }

        .safety-section h2 {
            text-align: center;
            font-size: 2rem;
            margin-top: 0;
            margin-bottom: 30px;
            color: var(--primary-color);
        }

        .safety-table {
            width: 100%;
            border-collapse: collapse;
        }

        .safety-table th, .safety-table td {
            padding: 15px;
            text-align: left;
            border-bottom: 1px solid var(--border-color);
        }

        .safety-table th {
            background-color: var(--primary-color);
            color: white;
            font-size: 1.1rem;
        }
        
        .safety-table th:first-child { border-top-left-radius: 8px; }
        .safety-table th:last-child { border-top-right-radius: 8px; }

        .safety-table tbody tr:nth-child(even) {
            background-color: #f8f9fa;
        }
        
        .safety-table tbody tr:hover {
            background-color: #e9ecef;
        }

        .safety-table td:first-child {
            font-weight: 700;
        }
        
        .action-required {
            background-color: #fff9e6;
            font-weight: 700;
            color: #997400;
        }

        footer {
            text-align: center;
            margin-top: 50px;
            font-size: 0.9rem;
            color: var(--light-text-color);
        }

        @media (max-width: 1200px) {
            .pathways-grid {
                grid-template-columns: 1fr;
            }
        }
        
        @media (max-width: 768px) {
             body {
                padding: 10px;
            }
            .container {
                padding: 10px;
            }
             header h1 {
                font-size: 2.2rem;
            }
            .pathway-card {
                padding: 20px;
            }
            .safety-section {
                 padding: 20px;
            }
             .safety-table th, .safety-table td {
                padding: 10px;
            }
        }
    </style>
</head>
<body>

    <div class="container">
        <header>
            <h1>Lipid Modification for CVD Prevention</h1>
            <p>A quick reference algorithm based on NICE CKS guidance (last revised July 2025). This is a memory aide and not a substitute for clinical judgment.</p>
        </header>

        <main>
            <div class="pathways-grid">
                <!-- PRIMARY PREVENTION PATHWAY -->
                <section class="pathway-card primary-path">
                    <h2><i class="fa-solid fa-shield-heart"></i>Primary Prevention</h2>
                    
                    <h3><i class="fa-solid fa-user-check"></i> 1. Identify Patient</h3>
                    <ul>
                        <li><strong>Offer Statin:</strong> QRISK3 &ge;10%, T1DM (>40y, >10y duration, or nephropathy), CKD, or all people with HIV (&ge;40y).</li>
                        <li><strong>Consider Statin:</strong> Age &ge;85, or QRISK3 <10% with clinical concern or patient preference.</li>
                    </ul>

                    <h3><i class="fa-solid fa-vials"></i> 2. Pre-Treatment Assessment</h3>
                    <ul>
                        <li>Discuss lifestyle modifications.</li>
                        <li><strong>Baseline Bloods:</strong> Lipid Profile, LFTs, eGFR, HbA1c.</li>
                        <li><strong>CK:</strong> Only for unexplained muscle symptoms.</li>
                        <li><strong>Refer to Specialist if:</strong> Total-C >9.0, non-HDL-C >7.5, or TGs >20 (urgent).</li>
                    </ul>

                    <h3><i class="fa-solid fa-pills"></i> 3. Initiate & Monitor</h3>
                    <p><strong>First-line:</strong> <strong>Atorvastatin 20 mg</strong> once daily.</p>
                    <div class="target-box">
                       <p><i class="fa-solid fa-bullseye"></i><strong>TARGET:</strong> >40% reduction in non-HDL Cholesterol</p>
                    </div>
                    <p>Review with lipid profile at 2-3 months.</p>

                    <h3><i class="fa-solid fa-arrow-trend-up"></i> 4. Optimize / Escalate</h3>
                     <ol>
                        <li>Discuss adherence & lifestyle.</li>
                        <li>Titrate <strong>Atorvastatin up to 80 mg</strong> daily.</li>
                        <li>If target still not met, add <strong>Ezetimibe 10 mg</strong> daily.</li>
                    </ol>

                    <div class="info-box">
                        <h4><i class="fa-solid fa-triangle-exclamation"></i>Statin Intolerance</h4>
                        <p>Stop & restart, reduce dose, switch statin, or try alternate-day dosing. If still intolerant, offer <strong>Ezetimibe 10 mg</strong>. Consider adding <strong>Bempedoic Acid</strong> if needed.</p>
                    </div>
                </section>

                <!-- SECONDARY PREVENTION PATHWAY -->
                <section class="pathway-card secondary-path">
                    <h2><i class="fa-solid fa-heart-pulse"></i>Secondary Prevention</h2>
                    
                     <h3><i class="fa-solid fa-user-check"></i> 1. Identify Patient</h3>
                    <ul>
                        <li>Offer statin to <strong>all adults with established CVD</strong> (MI, Angina, Stroke/TIA, PAD, Revascularization).</li>
                    </ul>

                    <h3><i class="fa-solid fa-vials"></i> 2. Pre-Treatment Assessment</h3>
                     <ul>
                        <li>Do not delay treatment. Discuss lifestyle concurrently.</li>
                        <li><strong>Baseline Bloods:</strong> Lipid Profile, LFTs, eGFR, HbA1c.</li>
                        <li><strong>CK:</strong> Only for unexplained muscle symptoms.</li>
                        <li><strong>Refer to Specialist if:</strong> Total-C >9.0, non-HDL-C >7.5, or TGs >20 (urgent).</li>
                    </ul>
                    
                     <h3><i class="fa-solid fa-pills"></i> 3. Initiate & Monitor</h3>
                    <p><strong>First-line:</strong> <strong>Atorvastatin 80 mg</strong> once daily.</p>
                     <p><em>(Use a lower dose for CKD, high AE risk, or patient preference).</em></p>
                    <div class="target-box">
                       <p><i class="fa-solid fa-bullseye"></i><strong>TARGET:</strong> LDL-C &le;2.0 mmol/L or non-HDL-C &le;2.6 mmol/L</p>
                    </div>
                    <p>Review with lipid profile at 2-3 months.</p>
                   

                    <h3><i class="fa-solid fa-arrow-trend-up"></i> 4. Optimize / Escalate</h3>
                    <ol>
                        <li>Discuss adherence; ensure max tolerated statin dose.</li>
                        <li>Add <strong>Ezetimibe 10 mg</strong> daily.</li>
                        <li>If target still not met, consider specialist options: <strong>Icosapent Ethyl</strong> (if TGs high), or <strong>injectables</strong> (PCSK9i/Inclisiran). Referral is appropriate.</li>
                    </ol>
                    
                     <div class="info-box">
                        <h4><i class="fa-solid fa-triangle-exclamation"></i>Statin Intolerance</h4>
                        <p>Offer <strong>Ezetimibe 10 mg</strong> monotherapy. If target not met, consider adding <strong>Bempedoic Acid</strong> or an injectable based on eligibility. Referral is appropriate.</p>
                    </div>
                </section>
            </div>

            <section class="safety-section">
                <h2><i class="fa-solid fa-clipboard-check"></i> Universal Monitoring & Safety</h2>
                <table class="safety-table">
                    <thead>
                        <tr>
                            <th>Test</th>
                            <th>When to Check</th>
                            <th>Action Required</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>Full Lipid Profile</td>
                            <td>Baseline, 2-3 months after change, then annually.</td>
                            <td>Guide treatment decisions based on targets.</td>
                        </tr>
                        <tr>
                            <td>LFTs (ALT/AST)</td>
                            <td>Baseline, 2-3 months after change, then at 12 months.</td>
                            <td class="action-required"><strong>If >3x ULN:</strong> Stop statin. Re-check in 4 weeks. Do not restart if still elevated.</td>
                        </tr>
                        <tr>
                            <td>Creatine Kinase (CK)</td>
                            <td><strong>Only if patient has persistent, unexplained muscle symptoms.</strong></td>
                            <td class="action-required"><strong>If >5x ULN:</strong> Stop statin. Re-check after 7 days. Do not restart if still elevated.</td>
                        </tr>
                    </tbody>
                </table>
            </section>
        </main>

        <footer>
            <p>This is a visual summary and does not replace the full NICE CKS guidance or professional clinical judgment.</p>
        </footer>

    </div>

</body>
</html>```